SEARCH

SEARCH BY CITATION

References

  • 1
    Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:24150.
  • 2
    Yarden Y. The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37:S3S8.
  • 3
    Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:655065.
  • 4
    Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2:12737.
  • 5
    Lin SY, Makino K, Xia W et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3:8028.
  • 6
    Oksvold M, Huitfeldt H, Stang E, Madshus I. Localizing the EGF receptor. Nat Cell Biol 2002; 4:E22, author reply E22-3.5.
  • 7
    Waugh MG, Hsuan JJ. EGF receptors as transcription factors: ridiculous or sublime? Nat Cell Biol 2001; 3:E209-11.
  • 8
    Ciardiello F, Tortora G. EGFR antagonist in cancer treatment. N Engl J Med 2008; 358:116074.
  • 9
    Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10:121.
  • 10
    Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr Pharm Des. 2007; 13:335867.
  • 11
    Kolch W, Calder M, Gilbert D. When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Lett 2005; 579:18915.
  • 12
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9:231626.
  • 13
    Gille J, Swerlick RA, Caughman SW. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2- dependent DNA binding and transactivation. EMBO J 1997; 16:7509.
  • 14
    Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13:50613.
  • 15
    Hadari YR, Doody JF, Wang Y et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor. J Clin Oncol 2004; 22 (abstract 234).
  • 16
    Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98:11598603.
  • 17
    Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev 1998; 12:50213.
  • 18
    Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:25765.
  • 19
    Thienelt CD, Bunn PA Jr, Hanna N et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J Clin Oncol 2005; 23:878693.
  • 20
    Robert F, Blumenschein G, Dicke K, Tseng J, Saleh MN, Needle M. Phase Ib/Ia study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:643 (abstract 2587).
  • 21
    Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:12018.
  • 22
    Vega-Villegas E, Awada R, Mesia L et al. A phase I study of cetuximab in combination with cisplatin or carboplatin and 5-FU in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Proc Am Assoc Cancer Res 2003; 22:2020.
  • 23
    Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351:33745.
  • 24
    Wilke H, Glyne-Jones R, Thaler J et al. Cetuximab plus irinotecan in heavily preatreated metastatic colorectal cancer progression on irinotecan. MABEL study. J Clin Oncol 2008; 26:533543.
  • 25
    Sobrero AF, Maurel J, Fehrenbacher L. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:23119.
  • 26
    Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:20408.
  • 27
    Tabernero J, Van Cutsem E, Díaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25:522532.
  • 28
    Bokemeyer I, Bondarenko A, Makhson H et al. FOLFOX-4 cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007; 25 (abstract 4035).
  • 29
    Folprecht G, Lutz MP, Schöffski P et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:45056.
  • 30
    Tabernero J, Cervantes A, Martinelli E et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24:1425 (abstract 3085).
  • 31
    Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25 (abstract 4000).
  • 32
    Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy – refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:165864.
  • 33
    Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:56778.
  • 34
    Vermorken JB, Mesia R, Vega E et al. Cetuximab extends survival of patients or recurrent or metastatic SCCHN when added to first line platinum-based therapy results of a randomized phase III (EXTREME) study. Late-breaking abstract presented at the 43rd American Society of Clinical Oncology Annual Meeting, Chicago, 1–5 June 2007.
  • 35
    Mendez MJ, Green LL, Corvalan JR et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997; 15:14656.
  • 36
    Mitchell EP, Rose L, Ramirez M, Jacobs M. Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer from two clinical studies. Annual Meeting Proceedings. Gastrointest Cancers Symp 2007; abstract 449.
  • 37
    Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:300315.
  • 38
    Weiner L, Belldegrun A, Rowinsky E et al. Update results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. J Clin Oncol 2005; 23:16S (abstract 3059).
  • 39
    Berlin J., Neubauer M., Swanson P. et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFR). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24(suppl. 18S): 3548.
  • 40
    Berlin J, Posey J, Tchekmedyian S et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6:42732.
  • 41
    Hecht JR, Mitchell E, Baranda J et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (1%) levels of epidermal growth factor receptor (EGFR). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24(suppl. 18S): 3547.
  • 42
    Malik I, Hecht JR, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005; 23:251s (abstract 3520).
  • 43
    Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:165864.
  • 44
    Amado RG, Wolf M, Peeters M et al. Wild-type K-ras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:162631.
  • 45
    Hecht JR, Mitchell E, Chidiac T et al. A randomized phase III of chemotherapy, bevacizumab, and panitumumab a compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:67280.
  • 46
    Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:180310.
  • 47
    Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:27986.
  • 48
    Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3:45965.
  • 49
    Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:26438.
  • 50
    Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96:11669.
  • 51
    Esteller M, Gonzalez S, Risques RA et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19:299304.
  • 52
    Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:39925.
  • 53
    De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:50815 [epub ahead of print on 12 November 2007.
  • 54
    Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:175765.
  • 55
    Van Cutsem E, Lang I, D'haens G et al. Kras status and efficacy in the first-line treatment of patients with metastic colorectal cancer (mCRC) treated with FOLFIRI with or without. The CRYSTAL experience. J Clin Oncol 2008; 26:5s (suppl; abstract 2).
  • 56
    Bokemeyer C, Bondarenko I, Hartmann J et al. Kras status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008; 26:178s (suppl; abstract 4000).
  • 57
    Cervantes A, Macarulla T, Martinelli E et al. Correlation of KRAS status (wild type [wt]versus mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2008; 26:2105 (suppl; abstract 4129).
  • 58
    Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:570512.
  • 59
    Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008; 14:17883.
  • 60
    Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol. 2007; 25:113443.
  • 61
    Murphy K, Travers P, Walport M. The humoral immune response. In: Janeway's immunobiology, 7th edn. New York: Garland Science, 2008.
  • 62
    Roda JM, Joshi T, Butchar JP et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13:641928.
  • 63
    Hudrisier D, Riond J, Mazarguil H, Gairin JE, Joly E. CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. J Immunol 2001; 166:36459.
  • 64
    Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol 2003; 4:815.
  • 65
    Hudrisier D, Aucher A, Puaux AL, Bordier C, Joly E. Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells. J Immunol 2007; 178:363747.
  • 66
    Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008; 181:291624.
  • 67
    Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 2008; 14:79816.
  • 68
    Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 2008; 181:812032.
  • 69
    Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008; 118:357481.
  • 70
    Capdevila J, Saura C, Macarulla T, Casado E, Ramos FJ, Tabernero J. Monoclonal antibodies in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2007; 33 (Suppl. 2): S2434. Epub 2007 5 November. Review. PubMed PMID: 17981431.
  • 71
    Borner M, Mingrone W, Koeberle D. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2006; 24:585 (abstract 3551).